6″-amino-6″-deoxygalactosylceramides

Details 6″-amino-6″-deoxygalactosylceramides 6″-amino-6″-deoxygalactosylceramides

2011-08-02

2011-08-02

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

07989423

ABSTRACT:
This invention relates to galactosylceramide compounds.

REFERENCES:
patent: 5242800 (1993-09-01), Jimenez et al.
patent: 5604207 (1997-02-01), DeFrees et al.
patent: 5767092 (1998-06-01), Koezuka et al.
patent: 5780441 (1998-07-01), Higa et al.
patent: 5785975 (1998-07-01), Parikh
patent: 5849716 (1998-12-01), Akimoto et al.
patent: 5958426 (1999-09-01), Moreau et al.
patent: 5963076 (1999-10-01), Shor et al.
patent: 6071884 (2000-06-01), Koezuka et al.
patent: 6417167 (2002-07-01), Maruyama et al.
patent: 6531453 (2003-03-01), Taniguchi et al.
patent: 6610835 (2003-08-01), Liotta et al.
patent: 6635622 (2003-10-01), Tomiyama et al.
patent: 6747010 (2004-06-01), Taniguchi et al.
patent: 7273852 (2007-09-01), Tsuji et al.
patent: 7273853 (2007-09-01), Or et al.
patent: 2002/0115624 (2002-08-01), Behar et al.
patent: 2003/0139351 (2003-07-01), Taniguchi et al.
patent: 2003/0153514 (2003-08-01), Yagita
patent: 2003/0157135 (2003-08-01), Tsuji et al.
patent: 2004/0127429 (2004-07-01), Tsuji
patent: 2004/0166554 (2004-08-01), Chamoles
patent: 2004/0266726 (2004-12-01), Yagita
patent: 2005/0192248 (2005-09-01), Tsuji et al.
patent: 2005/0222048 (2005-10-01), Tsuji et al.
patent: 2006/0019246 (2006-01-01), Tsuji et al.
patent: 2006/0073118 (2006-04-01), Bendelac et al.
patent: 2006/0211856 (2006-09-01), Tsuji et al.
patent: 2008/0095787 (2008-04-01), Teyton et al.
patent: 2009/0047299 (2009-02-01), Savage et al.
patent: 0988860 (2000-03-01), None
patent: 1016409 (2000-07-01), None
patent: WO 99/33475 (1999-07-01), None
patent: WO 03/009812 (2003-02-01), None
patent: WO 03/018039 (2003-03-01), None
patent: WO 03/105769 (2003-12-01), None
patent: WO 2005/000348 (2005-01-01), None
patent: WO 2005/102049 (2005-11-01), None
patent: WO 2006/029010 (2006-03-01), None
patent: WO 2006/083671 (2006-08-01), None
patent: WO 2007/050668 (2007-05-01), None
patent: WO 2007/118234 (2007-10-01), None
patent: WO 2008/005824 (2008-01-01), None
The Merck Manual, 16th Ed., 1999, pp. 339-342 and 1488-1490.
Kawano et al, Science, 1997, 278(28), 1626-29.
Zhou, X.T. et al, Organic Letters, 2001, 4(8), 1267-70.
Kawano et al, Science, 1997, 278(28), 1626-29.
Zhou et al, Organic Letters, 2002, 498), 1267-70.
U.S. Appl. No. 11/814,103, Teyton.
Ando, H. et al., “Solid-phase capture-release strategy applied to oligosaccharide synthesis on a soluble polymer support,” Angew. Chem. Int. Ed. (2001) 40:4725-4728.
Bendelac, A. et al., “Increased interleukin 4 and immunoglobulin E production in transgenic mice overexpressing NK1 T cells,” J. Exp. Med. (1996) 184:1285-1293.
Brigl, M. et al., “CD1: T cell function and antigen presentation,” Annu. Rev. Immunol. (2004) 22:817-890.
Brigl, M. et al., “Mechanism of CD1d-restricted natural killer T cell activation during microbial infection,” Nat. Immunol. (2003) 4:1230-1237.
Cantu, C. et al., “The paradox of immune molecular recognition of alpha-galactosylceramide: low affinity, low specificity for CD1d, high affinity for alpha beta TCRs,” J. Immunol. (2003) 170:4673-4682.
Fujii, S-I. et al., “Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein,” J. Exp. Med. (2003) 198:267-279.
Garrity, G.M. et al., Taxonomic Outline of the Procaryotic Genera, Bergey's Manual of Systematic Bacteriology, 2nd Edition (Apr. 2001).
Godfrey, D.I. et al., “Going both ways: immune regulation via CD1d-dependent NKT cells,” J. Clin. Invest. (2004) 114(10):1379-1388.
Godfrey, D.I. et al., “The elusive NKT cell antigen—is the search over?” Science (2004) 306:1687-1688.
Goff, R.D. et al., “Effects of lipid chain lengths in alpha-galactosylceramides on cytokine release by natural killer T cells,” J. Am. Chem. Soc. (2004) 126:13602-13603.
Gui, M. et al., “TCR beta chain influences but does not solely control autoreactivity of V alpha 14J28IT cells,” J. Immunol. (2001) 167(11):6239-6246.
Gumperz, J.E. et al., “Functional distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining,” J. Exp. Med. (2002) 195(5):625-636.
Hermans, I.F. et al., “NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells,” J. Immunol. (2003) 171:5140-5147.
Iida, N. et al., “A sulfated glucosylceramide from rat kidney,” J. Biol. Chem. (1989) 264(10):5974-5980.
Ismail, N. et al., “Overproduction of TNF-alpha b CD8+ type 1 cells and down-regulation of IFN-γ production by CD4+ Th1 cells contribute to toxic shock-like syndrome in an animal model of fatal monocytotropic ehrlichiosis,” J. Immunol. (2004) 172:1786-1800.
Karadimitris, A. et al., “Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography,” Proc. Natl. Acad. Sci. USA (2001) 98(6):3294-3298.
Kinjo, Y. et al., “Recognition of bacterial glycosphingolipids by natural killer T cells,” Nature (2005) 434:520-525.
Kronenberg, M., “Toward an understanding of NKT cell biology: progress and paradoxes,” Ann. Rev. Immunol (2005) 23:877-900.
Lee, P.T. et al., “Testing the NKT cell hypothesis on human IDDM pathogenesis,” J. Clin. Invest. (2002) 110(6):793-800.
Mattner, J. et al., “Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections,” Nature (2005) 434:525-529.
Matsuda, J.L. et al., “Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers,” J. Exp. Med. (2000) 192(5):741-753.
Petrovsky, N. et al., “Vaccine adjuvants: current state and future trends,” Immunol. Cell Biol. (2004) 82:488- 496.
Rock, K.L. et al., “Natural endogenous adjuvants,” Springer Semin. Immunopathol. (2005) 26:231-246.
Sidobre, S. et al., “CD1d tetramers: a powerful tool for the analysis of glycolipid reactive T cells,” J. Immunol. Methods (2002) 268:107-121.
Van Kaer, L., “Alpha-galactosylceramide therapy for autoimmune diseases: prospects and obstacles,” Nat. Rev. Immunol. (2005) 5:31-42.
Wu et al., “Bacterial glycolipids and analogs as antigen for CD1d-restricted NKT cells,” PNAS (2005) 102(5):1351-1356.
Zajonc, D.M. et al., “Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor,” Nat. Immunol. (2005) 6:810-818.
Zhou, D. et al.,“Lysosomal glycosphingolipid recognition by NKT cells,” Science (2004) 306:1786-1789.
International Search Report and Written Opinion of International Searching Authority of PCT/US2007/072451 dated Nov. 27, 2007.
International Search Report and Written Opinion of International Searching Authority of PCT/US06/002781 dated Dec. 20, 2006.
Supplementary Search Report of the European Patent Office for Application No. 03816701.1 dated Sep. 17, 2007.
European Office Action for Application No. 03816701.1 dated Nov. 29, 2007.
Written Opinion of International Preliminary Examining Authority for International Application No. PCT/US03/08530 dated Jun. 30, 2005.
International Search Report of International Searching Authority for Application No. PCT/US03/08530 dated Aug. 3, 2004.
International Search Report and Written Opinion of International Searching Authority for International Application No. PCT/US07/66250 dated Oct. 15, 2007.
Liu et al., “A modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells,”J. Immunol. Meth.(2006) 312 (1-2): 34-39.
Yu et al., “Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides,”Proc. Natl. Acad. Sci.(2005) 102 (9): 3383-3388.
Beaudoin, L. et al., “NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic b

Affiliated with

Also associated with

Rating

6″-amino-6″-deoxygalactosylceramides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 6″-amino-6″-deoxygalactosylceramides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6″-amino-6″-deoxygalactosylceramides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2760650